BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22429766)

  • 21. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
    Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
    Ertel P; Adalig B; Demircan I; Lartey B; Manyak MJ
    Int J Clin Pract; 2016 Oct; 70(10):870-880. PubMed ID: 27774780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.
    Egan KB; Suh M; Rosen RC; Burnett AL; Ni X; Wong DG; McVary KT
    Int J Clin Pract; 2015 Nov; 69(11):1316-25. PubMed ID: 26215544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
    Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
    Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program)].
    Shalekenov BU; Kuandykov YA; Shalekenov SB
    Urologiia; 2017 Oct; (5):42-47. PubMed ID: 29135141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Hernández C; Estivill E; Prieto M; Badía X
    Curr Med Res Opin; 2008 Apr; 24(4):1033-8. PubMed ID: 18302812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvements in Self-reported Lower Urinary Tract Symptoms With Prostate Health Supplement.
    Eliaz I; Weil E; Wilk B
    Altern Ther Health Med; 2018 Sep; 24(5):26-32. PubMed ID: 29428929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging Are Correlated With Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-assisted Radical Prostatectomy for Prostate Cancer.
    Grivas N; van der Roest R; Tillier C; Schouten D; van Muilekom E; Schoots I; van der Poel H; Heijmink S
    Urology; 2017 Sep; 107():196-201. PubMed ID: 28601562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Lang Kuhs KA; Hildesheim A; Trabert B; Kemp TJ; Purdue MP; Wentzensen N; Katki HA; Pinto LA; Loftfield E; Safaeian M; Chaturvedi AK; Shiels MS
    Cancer Epidemiol Biomarkers Prev; 2015 May; 24(5):825-32. PubMed ID: 25713025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
    Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
    Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
    Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
    Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection.
    Wu Y; Pan H; Wang WM; Xu D; Zhang L; Gu ZQ; Bai Q; Qi J; Huang HF
    Asian J Androl; 2017; 19(2):230-233. PubMed ID: 26763548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National trends in the use of PSA, urinalysis, and digital rectal exam for evaluation of lower urinary tract symptoms in men.
    Doolin J; Reese ZA; Mukamal KJ
    World J Urol; 2021 Mar; 39(3):855-860. PubMed ID: 32448971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.